ABARELIX – Drug Information
Generic Name: Abarelix
Therapeutic Classification: Chemotherapy
Abarelix for injectable suspension is a synthetic decapeptide with potent antagonistic activity against naturally occurring gonadotropin releasing-hormone (GnRH). It inhibits gonadotropin and related androgen production by directly and competitively blocking GnRH receptors in the pituitary. It is use in Oncology. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Mechanism of Action:
It is a gonadotropin releasing-hormone (GnRH) antagonist, prescribe for prostate cancer. It reduces testosterone (Hormone) level in your body, thus resulting involves in the growth of most prostate cancers.
It is administered by Parental Route.
Contraindication for Abarelix:
Contraindicated in women, children and individuals with known hypersensitivity.
Warnings and Precautions for Abarelix:
- Monitor testosterone blood levels, prostate specific antigen (PSA), or liver function tests level regularly while taking this medication.
- Caution should be exercised in patients with history of heart disease, including long QT syndrome, abnormal heart rhythm, liver disease, who are taking other medications, any allergy, and during breastfeeding.
- It may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to abarelix. Using abarelix alone, with certain other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks.
Adverse Reaction / Side Effect of Abarelix:
Hot flushes, pain, breast enlargement, breast pain/nipple tenderness, painful urination, urination frequency, nausea, urinary retention and urinary tract infection, Sleep disturbances, dizziness, syncope, headache, and fatigue, hypotension, peripheral edema, allergic reactions, back pain, constipation, swelling in the extremities, temporary redness of face and neck, upper respiratory tract infection and diarrhea.
The recommended dose is 100 mg administered intramuscularly to the buttock on Day 1, 15, 29 (week 4) and every 4 weeks thereafter.
Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F)
Trade Names/Brand Names:
International- | Plenaxis |